<code id='89ABE8B508'></code><style id='89ABE8B508'></style>
    • <acronym id='89ABE8B508'></acronym>
      <center id='89ABE8B508'><center id='89ABE8B508'><tfoot id='89ABE8B508'></tfoot></center><abbr id='89ABE8B508'><dir id='89ABE8B508'><tfoot id='89ABE8B508'></tfoot><noframes id='89ABE8B508'>

    • <optgroup id='89ABE8B508'><strike id='89ABE8B508'><sup id='89ABE8B508'></sup></strike><code id='89ABE8B508'></code></optgroup>
        1. <b id='89ABE8B508'><label id='89ABE8B508'><select id='89ABE8B508'><dt id='89ABE8B508'><span id='89ABE8B508'></span></dt></select></label></b><u id='89ABE8B508'></u>
          <i id='89ABE8B508'><strike id='89ABE8B508'><tt id='89ABE8B508'><pre id='89ABE8B508'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:focus    Page View:716

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In